Dow Jones (DJIA) Today: Goldman Sachs Group (GS) Leads The Day Higher, Pfizer (PFE) Lags

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading down 24.0 points (-0.1%) at 17,148 as of Tuesday, Sep 23, 2014, 9:36 a.m. ET. During this time, 19.5 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 298.7 million. The NYSE advances/declines ratio sits at 982 issues advancing vs. 1,681 declining with 279 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be Goldman Sachs Group (NYSE: GS), which is sporting a 66-cent gain (+0.4%) bringing the stock to $185.95. Volume for Goldman Sachs Group currently sits at 124,780 shares traded vs. an average daily trading volume of 2.5 million shares.

Goldman Sachs Group has a market cap of $82.04 billion and is part of the financial sector and financial services industry. Shares are up 4.5% year-to-date as of Monday's close. The stock's dividend yield sits at 1.2%.

The Goldman Sachs Group, Inc. provides investment banking, securities, and investment management services to corporations, financial institutions, governments, and high-net-worth individuals worldwide.

TheStreet Ratings rates Goldman Sachs Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, increase in stock price during the past year, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with a 56-cent decline (-1.9%) bringing the stock to $29.62. This single loss is lowering the Dow Jones Industrial Average by 4.24 points or roughly accounting for 17.7% of the Dow's overall loss. Volume for Pfizer currently sits at 2.4 million shares traded vs. an average daily trading volume of 23 million shares.

Pfizer has a market cap of $192.76 billion and is part of the health care sector and drugs industry. Shares are down 1.5% year-to-date as of Monday's close. The stock's dividend yield sits at 3.4%.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

null

If you liked this article you might like

Jim Cramer: You Have to Decide If You Want to Profit From This Moment

Jim Cramer: You Have to Decide If You Want to Profit From This Moment

Use My Knowledge to Buy Wisely: Cramer's 'Mad Money' Recap (Thursday 2/22/18)

Use My Knowledge to Buy Wisely: Cramer's 'Mad Money' Recap (Thursday 2/22/18)

Video: Jim Cramer Reveals Why His Charitable Trust Bought Goldman Sachs

Video: Jim Cramer Reveals Why His Charitable Trust Bought Goldman Sachs

Financial Stocks Make Great Buys After the Recent Market Downdraft

Financial Stocks Make Great Buys After the Recent Market Downdraft

TheStreet Podcast: Go Inside the Goldman Sachs Tech & Internet Conference

TheStreet Podcast: Go Inside the Goldman Sachs Tech & Internet Conference